Centre de Référence Maladies Rares

U1035 INSERM

Biothérapie des Maladies Génétiques Inflammatoires et Cancers (BMGIC)

FR : Biologie Fondamentale Appliquée à la Médecine

U1035Afficher le menu INSERM U1035 FR / EN

Christophe GROSSET

DR2 INSERMResponsable de l’équipe miRCaDe,
christophe.grosset@u-bordeaux.fr

PRÉSENTATION

Télécharger son CV PUBMED LINKEDIN RESEARCHGATE

Étudie les processus moléculaires et certaines voies de signalisation (Wnt, Anémie de Fanconi, RAS/RAF/MEK/ERK), gènes et microARNs impliqués dans la carcinogenèse du foie chez l’adulte (Carcinome hépatocellulaire) et chez l’enfant (hépatoblastome).

Publications

1. Grosset, C, CY Chen, N Xu, N Sonenberg, H Jacquemin-Sablon, and AB Shyu, A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell, 2000. 103(1): p. 29-40.
2. Solanilla, A, C Grosset, C Lemercier, M Dupouy, FX Mahon, K Schweitzer, J Reiffers, B Weksler, and J Ripoche, Expression of Flt3-ligand by the endothelial cell. Leukemia, 2000. 14(1): p. 153-62.
3. Harizi, H, M Juzan, C Grosset, M Rashedi, and N Gualde, Dendritic cells issued in vitro from bone marrow produce PGE that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol, 2001. 209(1): p. 19-28.
4. Grosset, C, R Boniface, P Duchez, A Solanilla, B Cosson, and J Ripoche, In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element. J Biol Chem, 2004. 279(14): p. 13354-62.
5. Solanilla, A, JM Pasquet, JF Viallard, C Contin, C Grosset, J Dechanet-Merville, M Dupouy, M Landry, F Belloc, P Nurden, P Blanco, JF Moreau, JL Pellegrin, AT Nurden, and J Ripoche, Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005. 105(1): p. 215-8.
6. Sagliocco, F, B Laloo, B Cosson, L Laborde, M Castroviejo, J Rosenbaum, J Ripoche, and C Grosset, The ARE-associated factor AUF1 binds poly(A) in vitro in competition with PABP. Biochem J, 2006. 400(2): p. 337-47.
7. Laloo, B, D Simon, V Veillat, D Lauzel, V Guyonnet-Duperat, F Moreau-Gaudry, F Sagliocco, and C Grosset, Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method. Mol Cell Proteomics, 2009. 8(8): p. 1777-88.
8. Simon, D, B Laloo, M Barillot, T Barnetche, C Blanchard, C Rooryck, M Marche, I Burgelin, I Coupry, N Chassaing, B Gilbert-Dussardier, D Lacombe, C Grosset, and B Arveiler, A mutation in the 3’-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet, 2010. 19(10): p. 2015-27.
9. Jalvy-Delvaille, S., M. Maurel, V. Majo, N. Pierre, S. Chabas, C. Combe, J. Rosenbaum, F. Sagliocco, and C.F. Grosset, Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65.
10. Maurel, M., S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet, F. Sagliocco, P. Bioulac-Sage, V. Pitard, H. Jacquemin-Sablon, J. Zucman-Rossi, B. Laloo, and C.F. Grosset, A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013. 57(1): p. 195-204.
11. Maurel, M., Dejeans, N., Taouji, S., Chevet, E. and C.F. Grosset. MicroRNA-1291-mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA, 2013. 19, 778-788.
12. Indersie, E, S Lesjean, KB Hooks, F Sagliocco, T Ernault, S Cairo, M Merched-Sauvage, A Rullier, B Le Bail, S Taque, M Grotzer, S Branchereau, C Guettier, M Fabre, L Brugières, M Hagedorn, MA Buendia, and CF Grosset, MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling. Hepatol Comm, 2017. 1(2): p. 168-183.
13. Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trezeguet V, Sagliocco F, Hagedorn M, Grosset CF. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget 2017;8(25):41211-26. doi: 10.18632/oncotarget.17162
14. Audoux, J, M Salson, CF Grosset, S Beaumeunier, JM Holder, T Commes, and N Philippe, SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines. BMC Bioinformatics, 2017. 18(1): p. 428.
15. Hooks, KB, J Audoux, H Fazli, S Lesjean, T Ernault, N Dugot-Senant, T Leste-Lasserre, M Hagedorn, B Rousseau, C Danet, S Branchereau, L Brugières, S Taque, C Guettier, M Fabre, A Rullier, MA Buendia, T Commes, A Raymond*, and CF Grosset*, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology, 2018 Jul;68(1):89-102. doi: 10.1002/hep.29672. *co-last authors. SIOP 2018 Poster Award.
16. Saad, A, B Liet, G Joucla, X Santarelli, J Charpentier, S Claverol, CF Grosset, and V Trézéguet, Role of O-glycanation and convertase maturation of the soluble Glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry, 2018 Feb 20;57(7):1201-1211. doi: 10.1021/acs.biochem.7b01208.
17. Indersie, E*, KB Hooks*, C Capdevielle, M Fabre, N Dugot-Senant, A Desplat, S Lepreux, A Merched, CF Grosset, and M Hagedorn, Tracking cellular and molecular changes in a species-specific manner during experimental hepatoblastoma progression in vivo. Oncotarget, 2018 Mar 1;9(22):16149-16162. doi: 10.18632/oncotarget.24598. * co-first authors.
18. D Loncaric, B. Stankovic, A Ghousein, M. Vreca, V. Spasenovski, A. Villacreces, C. Debeissat, C. Grosset, Zoran Ivanovic, Sonja Pavlovic1. Expression of miR- – 210 in human bone marrow derived mesenchymal stromal cells under oxygen deprivation conditions. Archives in Biological Sciences 2019, in press.

BREVETS

  • Use of Glypican-3-targeting microRNAs for treating liver cancer. n° B2058PC00; PCT/EP2016/065933 European patent UNIVERSITE DE BORDEAUX-INSERM
  • Use of catenin-beta 1-targeting microRNAs for treating liver cancer. n°B2059PC00; PCT/EP2016/065938 European patent UNIVERSITE DE BORDEAUX-INSERM-UNIVERSITE PARIS SUD - PARIS XI

LIENS

Retour à l'organigramme

INSERM U1035 - Université de Bordeaux
Work
146 rue Léo Saignat - Bât. TP zone sud, 4ème étage
33000 Bordeaux
Aquitaine
France
Work 0557 57 13 73/74
sarah.lesjean@inserm.fr